Nitroglycerin gel - Futura Medical

Drug Profile

Nitroglycerin gel - Futura Medical

Alternative Names: Eroxon; Glyceryl trinitrate topical gel - Futura; MED 2001; MED 2003; MED 2004; MED 2005; MED2002

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Futura Medical
  • Developer Futura Medical; MedPointe
  • Class Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Phase II Erectile dysfunction

Most Recent Events

  • 06 Mar 2017 Futura Medical files for patent protection with UK Intellectual Property Office for nitroglycerin gel in United Kingdom
  • 13 Sep 2016 Futura Medical completes a phase II trial in Erectile dysfunction in Poland and United Kingdom
  • 07 Sep 2016 Efficacy and adverse events data from a phase II trial in Erectile dysfunction released by Futura Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top